Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in non-cirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: the STORM-C-1 phase II/III trial
*Andrieux-Meyer I, Tan SS, Salvadori N, Simon F, Cressey TR, Rosaida MS, Abu Hassan MR, Omar H, Tee HP, Chan WK, Suresh K, Thongsawati S, Thetket K, Avihingsanon A, Khemnark S, Thanprasertsuk S, Piedagnel J-M, Sasikala S, Nur Asimah Z, Da Silva N, Brenner J, Pécoul B, Lallemant M, Shahnaz M